About US
Contact us
-
Sun Pharma brightens up Ilumya promos with psoriasis campaign encouraging self-loveWhile many campaigns for plaque psoriasis treatments focus on erasing the external effects of the condition, Sun Pharma’s latest Ilumya push is emphasizing the importance of looking inward, too. The2024/6/13
-
Lilly touts fibrosis win as it pads case for tirzepatide in MASHBack in February, Eli Lilly teased “clinically meaningful” results around the ability of its dual GLP-1/GIP med tirzepatide to curb fibrosis in patients with fatty liver disease. Now, the company is2024/6/13
-
FDA cracks down on China's Hengrui in scathing manufacturing write-upWhen the FDA comes knocking at your drug manufacturing facility, it’s best to play along. Unfortunately for Jiangsu Hengrui Pharmaceuticals, the company’s refusal to do so has resulted in a scathing2024/6/11
-
Vanda, after rejecting Future Pak offer, gets $466M takeout bid from Cycle PharmaIn recent months, Vanda Pharmaceuticals has been busy working to grow its commercial presence through itsacquisitionof Johnson & Johnson's Ponvory and itsrecent bipolar disorder approvalfor Fanap2024/6/11
-
Eli Lilly tipped to leapfrog Eisai, Biogen and take control of $13B Alzheimer's marketEisai and Biogen’s reign at the top of the Alzheimer’s disease market may be short-lived. While Leqembi is the only game in town today, Bloomberg Intelligence (BI) analysts expect Eli Lilly to come f2024/6/6
-
France's Orano Med debuts radiotherapy manufacturing plant near IndianapolisAmid a nuclear medicine boom, France’s Orano Med has chosen the U.S. to establish a manufacturing plant as it progresses on its radiopharma journey. Orano Med—which is working on targeted alpha thera2024/6/6
-
CDC recommends antibiotic doxycycline to protect against STIs after potential exposureDoxycycline, an antibiotic widely used to combat acne, malaria and Lyme disease, has beenrecommendedby the CDC for use in the United States by gay and bisexual men and transgender women after having2024/6/4
-
Kyowa Kirin to expand manufacturing footprint with $530M biologics plant in North CarolinaWith board approval in hand, Kyowa Kirin can move forward with plans to establisha $530 million manufacturing site in North Carolina. Construction on the state-of-the-art, 171,700-square-foot facilit2024/6/4
-
GSK, attempting to stage Blenrep comeback, bids adieu to combo studies with SpringWorks' OgsiveoDespite the recent approval of SpringWorks Therapeutics’ Ogsiveo, GSK is calling it quits on prior plans to wed the Pfizer spinout’s drug with its withdrawn cancer med Blenrep. SpringWorks on Thursda2024/5/30
-
With 2 planned launches, Boehringer Ingelheim looks to make a name for itself in oncologyWith 25 launches planned through 2030, Boehringer Ingelheim is gearing up for a busy few years. As a part of that, the German drugmaker is looking forward to flexing its oncology muscles with two new2024/5/30